drugset / Trial / NCT00704028
Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-01
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 15 mg/kg | Intravenous |
| Comparator | Iron dextran | Unknown | — | — |